% | $
Quotes you view appear here for quick access.

Oncothyreon Inc Message Board

  • aunty_jen aunty_jen Nov 19, 2012 1:53 PM Flag

    Did AF really actually say something that alluded to possible, maybe success for Stimuvax?

    AF said....

    "The German Merck is Oncothyreon’s development partner for Stimuvax, a cancer immunotherapy. Oncothyreon shares were cut in half last March because an interim analysis of the Stimuvax lung cancer study wasn’t robust enough to demonstrate a survival advantage. Expectations for Stimuvax are low right now, so Oncothyreon is another easy double if the cancer “vaccine” can buck the odds and win when the final results from the lung cancer study are announced."


    SortNewest  |  Oldest  |  Most Replied Expand all replies
1.16+0.03(+2.65%)May 31 4:00 PMEDT